Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2018-07-16 Regulatory Filings
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
FDA IND Clearance for First Clinical Programme
Regulatory Filings Classification · 99% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange. It details a specific corporate event: the receipt of FDA clearance for a clinical trial (MCY-M11) and provides a brief trading update for the six months ended 30 June 2018. Since it is a regulatory announcement regarding company news and trading status rather than a full financial report or a specific category like M&A or dividend notice, it falls under the RNS category.
2018-07-16 English
MaxCyte & NIH enter CRADA for Sickle Cell Disease
Regulatory Filings Classification · 100% confidence The document is a press release issued via the London Stock Exchange's Regulatory News Service (RNS). It announces a specific business development: a Cooperative Research and Development Agreement (CRADA) between MaxCyte, Inc. and the U.S. National Institutes of Health. Since this is a general regulatory announcement regarding a corporate partnership and does not fit into more specific categories like M&A, earnings, or dividends, it is classified as a Regulatory Filing (RNS).
2018-06-11 English
Preclinical Results at ASGCT Annual Meeting
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces the presentation of preclinical research results at a scientific conference (ASGCT). It does not contain financial statements, board changes, or regulatory filings of a mandatory nature, but rather serves as a corporate news update. Given the RNS header and the nature of the content (scientific/clinical progress update), it falls under the general regulatory announcement category.
2018-05-21 English
Notice of AGM and Annual Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 3,000 characters) from the London Stock Exchange's RNS service. It explicitly states that the 2017 Annual Report and Accounts and the Notice of Annual General Meeting have been sent to stockholders and provides a link to the company website to access them. Per the 'Menu vs Meal' rule, this is an announcement of the availability of reports rather than the reports themselves, making it a Report Publication Announcement (RPA).
2018-04-30 English
Notice of AGM and Annual Report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 3,000 characters) from the London Stock Exchange's RNS service. It explicitly states that the 2017 Annual Report and Accounts and the Notice of Annual General Meeting have been sent to stockholders and provides a link to the company website to access them. Per the 'Menu vs Meal' rule, this is an announcement of the availability of reports rather than the reports themselves, making it a Report Publication Announcement (RPA).
2018-04-30 English
CMO Appointment
Board/Management Information Classification · 100% confidence The document is an official announcement from MaxCyte, Inc. regarding the appointment of a new Chief Medical Officer, Dr. Claudio Dansky Ullmann. This falls under the category of management changes. The document is distributed via the London Stock Exchange's RNS (Regulatory News Service) system, which is standard for such corporate announcements. Since it specifically details a change in senior management, it is classified as MANG.
2018-04-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.